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ABSTRACT
Hypertension is one of the most common risk factors in the development of heart disease,
stroke and end stage renal failure. Sympathetic overactivity is believed to be one of the main
mechanism behind resistant hypertension. Renal denervation has been used to treat resistant
hypertension, although this procedure is an invasive one.
Spinal cord stimulation (SCS) is a known modality to treat ischemic pain, angina pectoris,
and peripheral vascular diseases. In previous studies in this laboratory, unilateral spinal cord
stimulation in spontaneously hypertensive rat (SHR) at 67% of the motor threshold increased
urinary sodium and water excretion significantly, without affecting mean arterial pressure (MAP)
or renal blood flow. Bilateral spinal cord stimulation in spontaneously hypertensive rats (SHR) at
67% of the motor threshold at the level of T11 – T12 increased urinary sodium and water
excretion significantly, while complete renal denervation eliminated the response.
To further understand the mechanism by which dorsal spinal stimulation increases
urinary sodium and water excretion, spinal stimulation was used in four groups of SHR, two intact
and two with dorsal rhizotomy of the renal nerve. SCS was applied at 67% of motor threshold at
the level of T11 – T12, to one group under each condition, intact or dorsal rhizotomized rats.
SCS produced a significant increase from baseline in urinary sodium excretion in rats with
intact renal nerves only. A similar increase was also observed when urine volume was analyzed.
Dorsal rhizotomy alone produced a significant increase in urine volume, and a decrease in MAP
in the rats also subjected to SCS.
These results indicates that the natriuretic effect of SCS is dependent on the antidromic
transmission of the electrical signal on the renal afferent nerves back to the kidney.
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CHAPTER 1
INTRODUCTION

Hypertension is defined as a medical condition that occurs when the force exerted by the
blood against the wall of the blood vessels is higher than normal (Thambar, 2015). According to
medical guidelines, hypertension is defined as a systolic blood pressure of ≥ 140 mmHg or
diastolic blood pressure ≥90mmHg. An increased blood pressure is a leading risk factor of
mortality and the third leading risk factor of disease globally (Murray et al., 2002).
Hypertension is one of the most common risk factors for the development of heart
disease (Thomas and Allison 2019). Hypertension is common in the community especially in
elderly patients, and is a contributing factor for heart disease, stroke, end stage renal failure, and
myocardial infarction. Approximately 68 million (31%) adults in the United States aged 18 years
and older had hypertension in 2015 (Thomas and Allison 2019). Of this adult population, 48
million were receiving pharmacological treatment but only 31 million had their blood pressure
controlled (Thomas and Allison 2019). The prevalence of hypertension is higher in men than
women and in African Americans (42.7%) when compared with Caucasians (27.8%) and Mexican
Americans (27.8%) (Murray et al., 2002).
The heart and the kidneys interact with each other to maintain homeostasis, using
neurohumoral regulatory mechanisms under normal condition. These regulatory mechanisms
become impaired during congestive heart failure, which results in renal dysfunction (Whelton et
al., 2005). Congestive heart failure results in the activation of the renal sympathetic efferent
nerve which causes the release of renin, sodium and water retention, and reduced renal blood
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flow (Whelton et al., 2005). Technological advancements have led to the development of renal
nerve ablation (destruction of the renal nerve) in the treatment of drug resistant hypertension in
humans. Several studies have been conducted to investigate the mechanism underlying the
effect of renal nerve denervation on sodium and water excretion and blood pressure; results
from these studies showed an increase in urine volume and natriuresis, increased mean renal
blood flow and decreased renal vascular resistance (Whelton et al., 2005). It is unclear if the
antihypertensive effect of renal nerve denervation is due to the selective ablation of the renal
afferent nerve or the renal efferent nerve, or a combination.
Spinal cord stimulation is an underutilized therapy which involves electrical stimulation
on the dorsal dura of the spinal cord, most commonly used to relieve chronic neuropathic pain.
Spinal cord stimulation was first proposed in 1967 as a treatment for pain (Shearly et al., 1967).
Spinal cord stimulation (SCS), also called neuro-stimulation, produces direct mild electric pulses
that interfere with pain stimuli reaching the brain. This has been used, not only in the treatment
of chronic pain, but also in a multitude of other disorders, such as angina, gastrointestinal and
urological diseases, epilepsy, psychiatric diseases and movement disorders (Foss and Osborn,
2016).
Spinal cord stimulation is also effective in improving blood flow, which is necessary for
relieving ischemic pain. Weak to moderate epidural stimulation of the spinal cord improves the
ischemic conditions by suppressing sympathetic activity to the effector organs. A study was
performed on anaesthetized rats to record the peripheral changes in the microcirculation of the
hind limbs during dorsal spinal stimulation. The stimulation parameters used in this study were
similar to the ones used in the clinic (50Hz, 0.2msec with a stimulation intensity that is 2/3 of that

3

evoking muscle contraction in the lower abdomen and legs). According to this study, spinal cord
stimulation increased blood flow to the skin and muscles of the hind limb after the electrode was
placed epidurally above the second lumber segment. This increased blood flow effect was
abolished when the ventral root innervating the paw of the hind limb was transected (Linderoth
et al., 1991, Linderoth and Foreman, 1999).
Previous studies in the Knoblich laboratory at Minnesota State University Mankato,
showed that unilateral dorsal spinal stimulation on the left dorsal spine at T11-T12 (the point in
which the renal sensory nerves enter the spine) increased urinary sodium excretion significantly,
without affecting renal blood flow or mean arterial pressure (Merger and Knoblich, 2003),
(Stearns and Knoblich 2007). Subsequently, it was demonstrated that renal denervation
eliminated the renal response to dorsal spinal stimulation. However, since renal nerve ablation
eliminates both afferent and efferent inputs to the kidney, it is unclear if the stimulation is acting
through inhibition of the renal efferent nerves, or retrograde transmission on the renal afferent
nerves. To selectively study the contribution of the renal afferent nerve to the natriuresis
response, a procedure termed dorsal rhizotomy was used (Schlaich et., 2012). This procedure
disrupts the afferent neural pathway from the kidney to the spinal cord by sectioning the dorsal
root just at the point it enters into the spinal cord at the level of T11-T12.
The proposed study will selectively ablate the renal afferent nerves in order to determine
the contribution of the renal sensory nerves to the increase in sodium and water excretion that
results from dorsal spinal stimulation.
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BACKGROUND
Physiology
The cardiovascular system consists of the heart, blood vessels, and blood. The heart and
the blood vessels help to transport vital nutrients throughout the body as well as remove
metabolic waste. The blood helps to protect the body against foreign microbes and toxins, as
well as regulate body temperature. Mean arterial blood pressure is a function of cardiac output
(CO), and total peripheral resistance (TPR) (Levy and Pappano, 2007). (BP=CO×TPR). Cardiac
output is a function of heart rate and stroke volume. Stroke volume is the volume of blood
pumped from the left ventricle per beat. The total peripheral resistance is regulated dynamically
by vasoconstriction or vasodilation in arteries and arterioles, which have abundant smooth
muscles in their walls. There are three groups of mechanisms that control the tone of these
arterial blood vessels which are; neuro-humoral, endothelial, and myogenic mechanism.
Neuro-humoral factors such as vasopressin and the sympathetic nervous system can raise
the blood pressure through vasoconstriction, which increases total peripheral resistance
(Mohrman and Heller, 2014). The myocyte and endothelial factors that maintain tonic arterial
constriction or tone, can be studied in isolated, cannulated small arteries. These arteries can
develop spontaneous myogenic tone when the lumen is pressurized (M.A Hill Et al. 2001).
According to the author studies they demonstrated that the arterioles can exhibit a state of
partial contraction or myogenic tone, which is dependent on the level of intraluminal pressure.
This means that an increase in pressure will result in vasoconstriction, whereas a decrease in
pressure leads to vasodilation. The physiological significance of this vasomotor response relates
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to its participation in local blood flow autoregulation, setting of basal peripheral vascular
resistance and regulation of capillary hydrostatic pressure (M.A Hill Et al. 2001).

Blood volume
The blood volume is determined by the amount of water and sodium ingested, excreted
by the kidney into the urine, and lost into the gastrointestinal tract, lungs, and skin. In order to
maintain the blood volume within a normal range, the kidney regulates the amount of water and
sodium that is lost in the urine. For example, if excessive sodium and water are ingested, the
kidney will excrete more sodium and water in the urine. The human kidneys are paired organs,
positioned bilaterally within the retroperitoneal space of the abdominal cavity at the level of T12
to L3. The kidneys are supplied with blood by paired renal arteries that enter the renal hilum. The
blood flows out of the kidneys through the paired renal veins which drains into the inferior vena
cava and back into the cardiovascular circulation. The kidneys main functions are the regulation
of water balance electrolyte and osmolarity, maintenance of pH homeostasis, and hormone
secretion. Among these numerous functions the kidney is also involved in the modulation of
blood pressure in the cardiovascular system (Winklewski et., 2017).
Blood flowing to the kidney is filtered at the glomerulus. These filtrates contain sodium,
water and other substances. As the filtrate travels through the proximal tubule, loop of Henle,
distal and collecting tubules, the concentration of sodium is altered as sodium is transported
across the tubular wall and into the renal interstitium and ultimately into the blood (Matthew
and Victor, 1999). Some of the renal tubules are permeable to water, so water leaves those
tubular regions along with sodium.
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Renin-Angiotensin-Aldosterone System (RAAS)
The renin-angiotensin-aldosterone system modifies blood pressure through a variety of
effects in different tissues, including alteration in vascular tone, augmentation of the activity of
the sympathetic nervous system, changes in the structure and function of the cardiovascular
beds, and renal salt and water homeostasis (Matthew and Victor, 1999). This system begins with
the production of renin in the kidney, specifically by the macula densa of the juxta-glomerular
apparatus. Renin release is stimulated by a decrease in effective arterial volume, renal perfusion
pressure or glomerular filtration rate, and by an increase in sympathetic activity as a result of
stimulation of the β1 adrenergic receptors (Matthew and Victor, 1999). Once in circulation, renin
catalyzes the conversion of angiotensinogen, which is released by the liver, to angiotensin I.
Angiotensin I which is an inactive form, comes in contact with angiotensin converting enzyme
(ACE), which sits on the surface of the vascular endothelium. This enzyme cleaves angiotensin 1
(inactive) to produce the active angiotensin II moiety. Angiotensin II activates G-protein coupled
receptors type 1 and 2 (AT1R, AT2R) (Mohrman and Heller, 2014).
Angiotensin II increases sodium transport along different sites of the proximal tubules,
thick ascending limb of the loop of Henle, distal and collecting tubules, thereby leading to greater
sodium retention. Another hormone known as aldosterone stimulates sodium transport from the
tubular fluid into the interstitium. Together these two hormones, angiotensin II and aldosterone,
provide a powerful mechanism for increasing sodium retention and fluid volume in the body. A
third hormone called anti-diuretic hormone (ADH), increases water permeability in the late distal
tubules and collecting tubules. Water follows sodium and the net effect of angiotensin II and
aldosterone is increased blood volume and pressure (O’ Callaghan Et al., 2013).
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Renal sympathetic nervous system
There are two ways in which the renal sympathetic nervous system affects blood
pressure. First it supplies the kidney with a rich network of efferent sympathetic fibers which is
located in the adventitia of the renal artery. The efferent sympathetic fibers are exclusively
noradrenergic. Secondly, kidney signals are returned to the central nervous system through
afferent sympathetic fibers, also located in the adventitia of the renal arteries. Afferent signals
from end organ sensors and baroreceptors as well as from the hypothalamus, cortex, and limbic
system are received and integrated by the autonomic centers in the medulla oblongata and
midbrain. Efferent signals are then transmitted to sympathetic pre-ganglionic neurons in the
inter-mediolateral column of the spinal cord. Fibers from neurons in the intermediolateral
column (T10 - T12, L1 - L2) extend through splanchnic nerves to post-ganglionic neurons located in
pre-vertebral ganglia. The post-ganglionic neuron then extends its fibers to the kidney through
the adventitia of the renal arteries (Bertog and Sievert, 2012).

Renal efferent sympathetic activity
The renal tubular cells of the kidney (Müller and Barajas, 1972), juxtaglomerular
apparatus (Barajas, 1964) and renal vasculatures (Ljunggvist and Wagermark, 1970, Barajas and
Wang, 1979) are supplied by the efferent sympathetic fibers, which also supply every aspect of
the kidney. The stimulation of the efferent fibers of the kidney results in the activation of the
adluminal basolateral Na/K adenosine triphosphatase (Aperia et al. 1992), thus promoting
sodium and water retention, renin secretion through the juxtaglomerular apparatus (Skott and
Jensen, 1993) and vasoconstriction of renal arterioles, thus, resulting in a general increase in
mean arterial pressure.
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Renin release stimulates the production of angiotensin II, thereby stimulating the release
of

mineralocorticoids

(aldosterone).

Aldosterone,

being

the

primary

endogenous

mineralocorticoid produced in the zona glomerulosa of the cortex of the adrenal gland, acts on
the kidney to promote the active reabsorption of sodium and passive reabsorption of water, as
well as mediating vasoconstriction. There appears to be a graded response depending on the
intensity of the sympathetic signal, such that with low frequency stimulation, renin secretion is
first affected, followed by tubular reabsorption and renal vascular tone at higher frequencies
(Koepke and Dibona, 1985).
According to Dibona, at any given renal perfusion pressure, renal sympathetic
denervation shifts the diuresis and natriuretic curve to the left i.e. an increase in water and
sodium excretion in denervated animals compared to the intact animal (Dibona GF, 1989). Thus,
it is assumed that an abrogation or disruption of the renal sympathetic efferent nerve constitutes
a therapeutic target in the management of hypertension (Dibona GF, 1989).

Renal afferent sympathetic activity
The kidney transmits signals via afferent sympathetic fibers, to neurons of the posterior
grey column of the ipsilateral spinal cord (Ciriello and Calaresu, 1983, Rosas-Arellano et al., 1999).
The cell bodies of the afferent sympathetic fibers are located in the dorsal root ganglia. Studies
using rat models have demonstrated that the cell bodies of the renal afferent sympathetic are
located at the level of T9- L1 (Kopp et al., 2002). The signals are then relayed from the afferent
fibers to the autonomic centers of the central nervous system as well as to the contralateral
kidney. The afferent fiber endings are found in all parts of the kidney; with the richest network
located in the renal pelvis.
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Two receptors types are responsible for the transmission of these signals, the
mechanoreceptors and the chemoreceptors. The mechanosensitive receptor relays information
regarding hydrostatic renal pelvic pressure, as well as renal arterial and venous pressure. The
chemosensitive receptors are activated by renal ischemia and changes in the chemical milieu of
the renal interstitium (Ciriello and de Oliveira, 2002). Afferent sympathetic neurons (dorsal root)
transmit signals to the central nervous system and communicate with sympathetic centers in the
central nervous system, thus regulating the overall sympathetic tone. This finding was
demonstrated in a study using animal model whose kidneys were injured by phenol injection.
The authors found that blood pressure rises after phenol injection, but the blood pressure rise
was prevented by prior dorsal rhizotomy (ye et al., 2002).

The authors concluded that

hypertension due to renal insufficiency in rats can be prevented by dorsal rhizotomy (Campese
and Kogosov, 1995).
Experiments using rat models have shown that the kidney afferent sensory nerve is
unmyelinated with an average diameter of 1.3 micrometer and is located in the renal pelvic wall
where afferent neurons are sensitive to stretch (Hausberg et al., 1974). An increase in renal pelvic
pressure stretches the renal pelvic wall, and activates the renal mechanoreceptors, leading to
afferent renal neurotransmission. Thus enhanced diuresis increases renal pelvic pressure, which
activates the renal mechanosensors, increasing renal afferent activation (Dagmara and Pawel,
2017). Another factor that affects renal nerve responsiveness is increased dietary sodium intake.
High sodium diets activate renal mechanoreceptors which inhibit renorenal reflexes, resulting in
the suppression of the renal sympathetic efferent nervous system, thereby minimizing sodium
reabsorption and increasing urinary sodium excretion (Hausberg et al., 1974).
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The sympathetic nervous system has a profound effect on the kidney’s ability to regulate
blood pressure, and, vice versa, the kidney has an important effect on the overall sympathetic
tone (Bertog and Sievert, 2012).

Renal denervation
In the animal model, renal nerve disruption Is achieved via various methods such as
bilateral dorsal rhizotomy, chemical sympathectomy (repeated daily subcutaneous injection of
guanethidine) or directly by physical stripping of the renal arteries followed by application of
phenol in alcohol (separation of the renal arteries from renal nerve with an insertion of thread
saturated with 10% phenol in 95% ethanol around the renal artery), systemic administration of
transient receptor potential (TRP) V1 receptor agonist, capsaicin or peri-axonal application of
capsaicin for a more selective ablation of the afferent renal nerve (Jason D et al. 2014).
Resection of the renal nerve was first proposed in the early 1920s for the treatment of
nephralgia and pain induced by hydronephrosis in humans. Denervation of the renal afferent
sympathetic nerve from the thoraco-lumber section, produced a marked improvement in
patients with hypertension (Papin and Ambard, 1924). Bilateral nephrectomy has been shown to
normalize sympathetic activity (Smithwick, 1951) because the procedure eliminated the renal
afferent nerve endings.
As technologies advanced, safe and less invasive renal denervation techniques were
developed which include: radiofrequency energy delivered into the lumen of the renal artery via
catheter based electrodes (single or multiple), externally focused ultrasounds, and chemical
infusion of low doses of alcohol into the renal artery.
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Out of these three proposed techniques, the most widely used is the radiofrequency
energy delivered into the lumen of the renal artery via catheter-based electrodes, although there
is currently no biomarker of successful denervation available. These demonstrate a 47% decrease
in neurotransmitters released from the kidney, thus decreasing sympathetic renal activity
(Winklewski et., al 2017). Complications of this procedure include vasospasm, renal artery
stenosis, and anesthetic issues such as transient bradycardia have been recorded due to
fluctuations of systemic blood pressure. Another method used to disrupt afferent renal nerve
signaling is systemic administration of the transient receptor potential (TRP) V1 receptor agonist
otherwise known as capsaicin. Jason et al., demonstrated that capsaicin not only ablates small
unmyelinated C-fibers, but also destroys afferent neurons in the kidney; however, it is not specific
for renal afferents since systemic administration of capsaicin has been shown to cause
degeneration of transient receptor potential V1 + sensory fibers throughout the body (Jason et
al., 2014). Jason et al., went further to look at the selective role of renal afferent signaling in the
regulation of renal and cardiovascular function. In order to go about their study, they needed to
come up with a technique that selectively denervated the renal afferent nerve, thus leaving the
efferent renal nerve intact. The approach they used was peri-axonal application of capsaicin to
the renal nerve, because the majority of the renal afferent nerves are unmyelinated, sensitive to
capsaicin and TPRV1 receptors are localized along the axons of the sensory fibers as well as nerve
terminals. Capsaicin is able to bind to these receptors and selectively denervate the nerve (Jason
et al., 2014).
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Renorenal Reflex (Renal Mechano-Sensory Nerve)
An increase in the activity of the renal efferent sympathetic nerve, increases renal
afferent nerve activity, which in turn decreases renal efferent sympathetic nerve activity through
the activation of a negative feedback mechanism (Inhibitory Renorenal Reflex) (Kopp et al.,
2007). Increased dietary sodium intake, increases renal pelvic pressure, which activates the renal
mechanosensory nerves in the renal pelvis (Kopp et al., 2002). Due to the activation of the
renorenal reflex in high salt conditions, increased renal afferent activity suppresses renal efferent
sympathetic nerve activity which results in an increase in sodium excretion.
The importance of the reno-renal reflex is to maintain sodium and water homeostasis. It
is underlined by the low activation threshold which is approximately 3mmHg pressure in the renal
pelvis, and its abolition results in salt-sensitive hypertension. In the absence of an intact renal
afferent nerve, rats on a diet high in sodium become hypertensive. Previous studies have shown
that afferent renal nerve activity and urinary sodium excretion responses to increased renal
pelvic pressure are enhanced by a high sodium diet and suppressed by a low sodium diet. The
mechanism involved in the activation of the renal mechanosensory nerves as a result of
stretching the renal pelvic wall involves the induction of the cyclooxygenase-2 (COX-2) which
leads to the increase in renal pelvic synthesis of prostaglandin E2 (PGE2). Prostaglandin E2 (PGE2)
will in turn increase the release of substance P, through the activation of cyclic adenosine
monophosphate protein kinase A (cAMP-PKA) signal transduction pathway. Substance P
activates the afferent renal nerves by stimulating neurokinin-1 receptors in the renal pelvic area
(Kopp et al., 2008).
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Types of Hypertension
Primary Hypertension
Primary hypertension, otherwise known as essential hypertension, is an increased blood
pressure that does not have a known secondary cause. Genetic factors are known to play a role
in this kind of hypertension, accounting for 30-50% of individual cases. Other factors responsible
for primary hypertension are certain environmental and lifestyle changes (Shradha et al, 2018).
Commonly implicated medications and foodstuffs that increase blood pressure are non-steroidal
anti-inflammatory

medications,

corticosteroids,

calcineurin

inhibitors,

stimulant

sympathomimetics, female hormone replacements, hormonal oral contraceptives, excess
sodium diet, alcohol and illicit drugs. Life style choices like a sedentary lifestyle and a diet poor in
fruits and vegetables, as well as carbohydrate rich diets that lead to obesity, also contribute to
increases in blood pressure (Shradha et al, 2018).
Dysregulation of the renin angiotensin aldosterone system has been associated with
essential hypertension. Genetic changes or modifications in the angiotensinogen locus produces
extra copies of angiotensinogen, which in turn increase the plasma angiotensinogen level and
subsequently angiotensin II. This mechanism has been associated with hypertension in transgenic
mice as well as in humans with essential hypertension. In spontaneously hypertensive rats (SHR),
blockade of the central renin angiotensin aldosterone system with the intraventricular
administration of an angiotensin type 1 receptor blocker has successfully prevented hypertension
in pre-hypertensive SHR. According to the study, the authors concluded that over activity of the
brain renin angiotensin aldosterone system was implicated in hypertension in spontaneously
hypertensive rats (O’Callaghan et al, 2013).

14

Secondary hypertension
Secondary hypertension is an increase in blood pressure that occurs as a result of
secondary identifiable causes such as kidney diseases, or conditions that affect the arteries,
heart, and endocrine system. This can also occur during pregnancy. This kind of hypertension
accounts for 5-10% of hypertensive patients. Proper treatment can control both the underlying
condition and the high blood pressure, which can reduce the risk of serious complications,
including heart disease, kidney failure and strokes.
The prevalence of secondary hypertension increases to 20-60% in young patients (<30
years of age) and patients with resistant hypertension. The most common secondary causes
found in resistant hypertension are obstructive sleep apnoea (OSA), which results in sympathetic
overdrive, and hyperaldosteronism (Conn’s adenoma or bilateral adrenal hyperplasia causing
mineralocorticoid excess) (Shradha et al, 2018).
Blood pressure measurement
Blood pressure is an unstable biological variable, which is subject to seasonal, circadian,
hormonal and immediate external influences. As such, a single point measurement is unlikely to
be a representation of an individual’s usual blood pressure (National Institute for Health and Care
Excellence, 2011, Galderisi et al, 2013). Thus it is important to remember this when diagnosing
and treating patients with this condition. Multiple blood pressure readings should be taken in
one sitting, as well as repeat blood pressure measurement over several clinical encounters. This
practice is important in order for patients to obtain readings that more closely resemble the usual
blood pressure readings (Galderisi et al, 2013).
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Treatment of Hypertension
The pathophysiological progression of hypertension is important in terms of guiding
treatment regimens (Fisher and Paton, 2012). There has been a remarkable improvement in the
treatment of hypertension over the past 50 years. Despite these advances, it is estimated
worldwide that 1 billion people still remain hypertensive. The global prevalence is projected to
exceed 1.15 billion by 2025 (Mittal and Singh, 2010). This results from multiple factors, including
under-diagnosis of the condition and treatment noncompliance.
There are three different strategies used in lowering blood pressure, which are;
traditional pharmacological therapies, alternate therapeutic strategies and surgical therapeutic
strategies
Traditional pharmacological therapies
The success of a treatment paradigm in lowering blood pressure in patients with resistant
hypertension, with evidence of cardiovascular damage varying from slight to marked, has been
achieved via targeting the sympathetic nervous system activity. Traditional therapy involves the
use of pharmacological drugs to lower blood pressure. At present, angiotensin II converting
enzyme (ACE) inhibitors, angiotensin II type 1 (AT1) receptors antagonists, β receptor blockers,
calcium channel blockers, and diuretics represent the primary pharmacological treatment
options in patients with hypertension (Chobanian, 2009). The therapeutic agents could be
prescribed as either a monotherapy or in combination.
In general, in patients with uncomplicated essential hypertension, minimal alteration in
muscle sympathetic nervous activity has been reported in studies examining the effects of long
term administration of traditional antihypertensive agents such as angiotensin converting
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enzymes inhibitors (ACE) (Grassi et al., 1998) or angiotensin 1 receptor antagonists (Krum et al.,
2006). β-adrenergic blockers have also been demonstrated to have a neutral effect on central
sympathetic outflow, particularly when reductions in heart rate are accounted for (Wallin et al.,
1984). It is interesting to know that chronic administration of some traditionally used
antihypertensive compounds such as diuretics and dihydropyridine calcium channel blockers, can
actually stimulate central sympathetic outflow (Grassi, 2004). Thus the sympathetic effects of
traditional blood pressure lowering drugs need to be carefully considered. (Fu et al., 2005)
demonstrated that successful blood pressure lowering with combined angiotensin 1 receptor
antagonists and diuretics, in a group of newly diagnosed patients with moderate essential
hypertension, was associated with chronic exacerbation of muscle sympathetic nervous activity,
possibly due to baroreflex unloading (lowered blood pressure sensed by the baroreflex). These
studies identify the inadequacies of traditional hypertensive drug treatments in treating
excessive central sympathetic outflow in hypertension.

Pathogenesis of resistant hypertension
The sympathetic nervous system has been implicated to be the cause of resistant
hypertension (Katholi et al., 2010, Grassi, 2009, Shultz et al., 2007). Resistant hypertension is
defined as a persistent increase in blood pressure, despite taking two or more medications of
different classes, including ACE inhibitors combined with diuretics and calcium channel blockers
(Fisher and Paton, 2012). The contribution of the renal sympathetic efferent and afferent nerves
to resistant hypertension and chronic renal failure have been recognized. In the case of resistant
essential hypertension, the renal vascular bed receives greater sympathetic activation than any
other vascular beds. Increased stimulation of the renal sympathetic results in increased renal
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vascular resistance, which in turn causes an increase in plasma renin activity. The increased
renin, via angiotensin II and aldosterone, facilitates sodium and water retention, and decreases
renal blood flow (Katholi et al., 1977, Katholi et al. 2010).
The reno-renal inhibitory reflex is attenuated when renal function is impaired, for
example in ischemic kidney disorders. Increased afferent renal nerve activity contributes to the
increased sympathetic nerve activity observed in patients with resistant hypertension. This is to
say that an increase in renal afferent nervous activity will cause a positive feedback increase in
renal efferent sympathetic activity, as hypertension worsens and becomes resistant to
treatment. This concept was supported in a study with five patients that couldn’t undergo renal
denervation in their initial trial due to short renal arteries or dual renal arteries. This allowed their
hypertension to worsen over the years despite optimal treatment being offered to them. In view
of these sympathetic mechanisms, denervation of both the afferent and efferent renal nerves
should result in long term attenuation of resistant hypertension.
According to this article (Katholi et al., 2010), therapeutic denervation of the sympathetic
renal nerve in patient with resistant hypertension will result in a 14mmHg decrease in systolic
blood pressure at 1 month, which can be improved to a 27mmHg decrease in systolic blood
pressure by 12 months (Krum et al., 2009). The article further suggested that the response seen
was due to the destruction of the afferent renal nerves (Fletcher, 2001). Studies done on animals
have shown that selective denervation of the renal afferent sensory nerves by dorsal rhizotomy
not only lowered blood pressure but also reduced end organ damage caused by excessive
sympathetic nervous system activity (Campese et al., 1995, Hausberg et al., 2002, Dibona, 2003).
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Several studies have provided evidence that the kidney is a sensory organ (Katholi et al,
1984, Ye et al, 2002, Katholi et al, 2010). The renal nerves contain multiple afferent unmyelinated
fibers and some thinly myelinated fibers that carry impulses to the contralateral kidney, as well
as centrally (Katholi et al, 2010). The renal afferent nerve has been shown to be involved in both
renal-renal regulation and cardiovascular regulation. Animal studies have shown the involvement
of renal afferent nerve activity in renovascular or renal failure hypertension (Katholi et al, 1983,
Katholi et al, 1984, Kopp et al, 2003, Schlaich et al, 2009), and that selective renal denervation
will attenuate this hypertensive effect. According to these studies, since the renal afferent nerve
is likely the cause of resistant hypertension, there must be a signal that is being sent continuously
from the renal afferent nerve that enhances the central sympathetic nervous system activity. The
authors believed the signal to be adenosine and the receptor to likely be a chemoreceptor. During
increased metabolic activity, adenosine is known to be released by the renal proximal tubular
cells into the tubular fluid, where it stimulates chemoreceptive nerve endings in patients with
hypertension and heart failure (Katholi et al, 2010).
Studies in animals have shown that stimulation of adenosine-sensitive nerve endings
within or near the renal pelvis activates central sympathetic nervous activity through the afferent
renal nerve, resulting in hypertension (Katholi et al, 1983, Katholi et al, 1984). Intrarenal
adenosine has also been found to be elevated in patient with a stenosed renal artery and patients
with metabolically stressed kidneys (Katholi et al, 1995).
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Alternate therapeutic strategies
Central sympatholytic
Stimulation of α2 or imidazoline receptors within the central nervous system, directly
reduces excessive central sympathetic outflow in hypertension (Fisher and Paul, 2010). Over the
years the oral administration of either clonidine which is α2 and imidazoline receptor agonist, or
moxonidine which is a selective imidazoline receptor agonist, has been shown to effectively
reduce sympathetic nervous system activity and blood pressure in essential hypertension (Esler
et al., 1997, Wenzel et al., 1998). However, both of these two medications have been reported
to have an unpleasant side effect such as drowsiness, dizziness and orthostatic intolerance. The
side effects of these drugs may to some extent be circumvented with effective dosing. A second
generation imidazoline binding agent such as rilmentidine, has been reported to be more
promising and beneficial in reducing sympathetic nervous system activity and blood pressure
(Esler et al., 2004). It has been reported to be well tolerated by patients and it is effective in
reducing left ventricular hypertrophy in patients with essential hypertension (Koldas et al., 2003).
Central nitric oxide
Several studies have shown that nitric oxide may be a therapeutic target to arrest
excessive central sympathetic activation in hypertension. Nitric oxide is a signaling molecule that
is synthesized from the conversion of amino acid L-arginine to L-citrulline by the enzyme nitric
oxide synthase (NOS). There are three isoforms of nitric oxide synthase, namely the endothelial
(eNOS), neuronal (nNOS) and inducible (iNOS) nitric oxide synthase. Endothelial and neuronal
nitric oxide synthase are both expressed in mammalian cells.
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In mammals, the endothelial isoform is a primary signal generator in the control of
vascular tone, insulin secretion, and airway tone. It is involved in the regulation of cardiac
function and angiogenesis (growth of new blood vessels). The neuronal isoform is involved in
nervous system development. It functions as a retrograde neurotransmitter involved in long term
potentiation, thus is important in learning and memory (Fisher and Paul, 2010).
All nitric oxide isoforms are expressed in the central and peripheral nervous system.
Several studies have suggested that nitric oxide is a key signaling molecule involved in the tonic
restraint of sympathetic outflow from the brain stem (Thomas et al., 2001). According to these
studies, systemic infusion of a competitive nitric oxide synthase inhibitor in healthy humans
causes sympathetic activation and marked elevations in blood pressure (Lepori et al., 1998,
Sander at al., 1999, Young et al., 2009).
Aerobic exercise training
Aerobic exercise training is one of the non-pharmacological approaches to reducing blood
pressure in patients with hypertension. The mechanism behind this likely involves an alteration
in both neuro-humoral and neural cardiovascular control.
Laterza et al. demonstrated that 4 months of moderate intensity aerobic exercise training
in never treated hypertensive patients significantly reduced muscle sympathetic nervous system
activity and increased arterial baroreflex regulation of sympathetic nervous system activity
(Laterza et al., 2007). Exercise has been shown to elicit an increase in peripheral and central nitric
oxide synthase activity (NOS) (Mueller, 2007). This is associated with an upregulation of central
antioxidants and downregulation of central pro-oxidants (Zucker et al., 2004).
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Weight loss
Over the years there has been a strong association between weight gain and hypertension
(Brown et al., 2000). Grassi et al. demonstrated that hypertension due to obesity results in an
elevation in muscle sympathetic nervous system activity and renal nor-adrenaline spillover
(Grassi et al., 2000). Weight loss following caloric restriction alone, or in combination with
exercise training, has been associated with reductions in muscle sympathetic nervous system
activity (Straznicky et al., 2005). The most effective therapeutic strategy for obesity related
hypertension, particularly in the western world, is weight loss, which will in turn reduce
sympathetic nervous system activity and lower blood pressure.
Reduction in psychosocial stress
Stress generally has been implicated in the pathogenesis of essential hypertension (Esler
et al., 2008). Although work related stress may result in a daytime ambulatory blood pressure
increase, the mechanism linking stress to hypertension seems to be complex and multifactorial,
although the sympathetic nervous system is known to play an important role (Esler et al., 2008).
Elevated stress has been associated with an increased risk of atherosclerosis and acute
cardiovascular events (Rosengren et al., 2004). Thus, stress reduction may be beneficial in
lowering sympathetic nervous system activity and blood pressure (Rozanski et al., 1999).
Surgical therapeutic strategies
Due to the prevalence of resistant hypertension, more invasive approaches to reducing
blood pressure were developed. These include renal sympathetic denervation and carotid sinus
baroreflex stimulation.
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Surgical renal denervation has been used over the years to treat resistant hypertension
even before the availability of antihypertensive medications. Due to the fact that the procedure
may result in several complications and had high rates of postoperative morbidity and mortality,
it became less utilized. Renal denervation is done by either a surgical method or via catheter
ablation. In the catheter-based method, radiofrequency energy is delivered to the renal artery
wall by the insertion of an intravascular catheter through the common femoral artery. In 2009,
Krum and his colleagues performed a trial of catheter-based renal sympathetic denervations in
patients with resistant hypertension. The authors demonstrated a marked reduction in blood
pressure (-27mmHg systolic/-17mmHg diastolic) a year after the procedure (Krum et al., 2009).
The benefits of the catheter-based approach in comparison to surgical sympathectomy, are that
it is brief with a median procedure time of 38 min, has no deleterious effect on renal function,
and can be performed without long term complications (Fisher and Paul, 2010).
Renal denervation interrupts both afferent and efferent renal sympathetic nerves
(DiBona et al., 2013). Renal efferent denervation decreases blood pressure through reduced
renal vasoconstriction, renin secretion and sodium retention, and increased renal blood flow.
Renal afferent denervation suppresses sympathetic nervous activity systemically and also lowers
muscle sympathetic nervous activity by 66% (Fisher and Paton, 2012).
The surgical implantation of a device that elicits stimulation of the carotid baroreflex, has
been used to target the sympathetic nervous system in resistant hypertension. Brauwald et al.,
demonstrated that a carotid nerve stimulator implanted in patients for the treatment of
intractable angina pectoris elicited consistent reductions in blood pressure and symptomatic
relief of angina (Braunwald et al., 1970). The complication with technological procedures such as
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battery life and current leakage, at the time limited the widespread use of the device (Fisher and
Paton, 2012, Uppuluri et al., 2009). Chronic baroreflex activation by a device decreases blood
pressure, glomerular filtration rate, plasma renin activity, norepinephrine level, and sodium
reabsorption. This is known to be more beneficial in obesity related hypertension (DiBona et al.,
2013). This procedure involves the implantation of an electrode around the carotid sinus
adventitia, such that only the baroreceptors are stimulated, without stimulating the
chemoreceptors and mechanoreceptors (Fisher and Paton, 2012).
Deep Brain Stimulation
Electrical stimulation of the periaqueductal grey matter area, elicited a sustained
reduction in blood pressure in a 58 year old man treated for neuropathic facial pain (Fisher and
Paul, 2009). The reduction in blood pressure was followed by a reduction in pain. Chronic
stimulation of the periaqueductal grey area can improve hypertension to the point that
medication can be discontinued (Fisher and Paton, 2012).

Spinal cord stimulation
Spinal cord stimulation is achieved by placing an electrode in the epidural space over the
dorsal column, a few levels above the affected spinal segments. Mild to moderate electrical
pulses at various frequencies, usually 50-60 Hz, are delivered to the spinal cord to elicit
paresthesia in the painful region.
Spinal cord stimulation dating back to the 1960’s, has become part of routine pain
therapy; it is estimated that over 30,000 spinal cord stimulation systems have been implanted
every year worldwide (Linderoth and Meyerson, 2010). Guan et al. studied the effect of spinal
cord stimulation on pain inhibition, along with with Dr. Srinavasa Raja, who was a senior
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researcher at Johns Hopkins University, Baltimore, Maryland. They looked at the physiological
basis for the pain suppressive effect of spinal cord stimulation, which was a widely used pain
inhibition therapy at the time (Guan et al, 2010). The authors designed an extensive
electrophysiological study, using animal models with neuropathic pain. They later went on to
demonstrate that spinal cord stimulation (SCS) may markedly attenuate neuronal responses in
the spinal dorsal horn to both natural innocuous pain and electrical noxious stimuli applied to a
nerve injured hind paw (Guan et al, 2010).
Spinal cord stimulation is an outgrowth of the well-known gate control theory postulated
by Melzack and Wall in 1965 (Melzack and Wall, 1965). They proposed that a mechanism in the
dorsal horn of the spinal cord acts like a gate that inhibits or facilitates transmission from the
body to the brain on the basis of the diameters of the active peripheral fibers, as well as the
dynamic actions of brain processes. Electrical current activates large afferent fibers that close the
gate of pain transmission, while noxious stimuli activates small sized afferent nerves that send
messages to the brain. The gate control theory serves as the basic foundation for explaining the
mechanism of spinal cord stimulation, even though details of the theory still remain controversial
and require additional studies.
In the 1970’s and 1980’s, a number of experimental studies appeared with the aim of
investigating the mode of action of spinal cord stimulation. The limitation of these studies is that
they were performed on anaesthetized normal healthy animals, subjected to acute, noxious
stimuli, thus their relevance for investigating the effect of spinal cord stimulation on neuropathic
pain was questionable. It was not until 1994 that spinal cord stimulation was experimentally
studied in an animal model of neuropathic pain (Meyerson et al, 1994, Linderoth et al, 1995).
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The hyperexcitability demonstrated by multimodal wide dynamic range cells in the dorsal
horn seems to be related to increased basal release of glutamate, which is an excitatory amino
acid, and an inhibition of gamma aminobutyric acid (GABA) which is an inhibitory
neurotransmitter (Stiller et al, 1996, Cui et al 1997).
Spinal cord stimulation (SCS), may suppress the enhanced responsiveness of this
multimodal wide-dynamic range cells to innocuous peripheral stimuli. Guan et al, reported that
dorsal column stimulation did suppress the wide-dynamic range neuronal response to peripheral
electrical activation of C-fibers, although the effect was also observed in the sham operated rats.
The authors later suggested that there was no clear evidence that spinal cord stimulation is
helpful for alleviating acute nociceptive pain. This finding contradicts with the gate control theory
by Melzack and Wall in 1965, from which spinal cord stimulation emerged (Melzack and Wall,
1965). In 1974, it was demonstrated that spinal cord stimulation in patients did not influence
pain perception, but effectively attenuated tactile and pressure allodynia (Lindblom and
Meyerson 1975). A study in 1995 showed that there was no effect of dorsal column stimulation
on the C-fiber component of the flexor reflex in nerve injured rats.

Spinal Neurochemical Mechanisms
Gamma Amino Butyric Acid (GABA)
Aβ fiber input and GABA release activates GABAergic inhibitory interneurons in the
superficial laminae of the dorsal horn (Daniel and MacDermott, 2009, Schoffnegger et al, 2006).
GABA is an important inhibitory neurotransmitter in the gate control mechanism. In models with
neuropathic pain, spinal cord stimulation increases the spinal release of GABA in animals that
responded well to the analgesic effect of spinal cord stimulation, thus subsequently resulting in
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a decrease in glutamate and aspartate release (Linderoth et al, 1996). The authors suggested that
the GABAb receptor is responsible for the aforementioned effect, and it plays a more important
role than the GABAa receptor in mediating the inhibitory effect (Meyerson et al, 1997).
The inhibition of the wide dynamic range neuronal hyperexcitability and animal pain
behavior was closely associated with the time course of elevated GABA levels in the dorsal horn
after spinal cord stimulation. Shealy et al. proposed a mechanism through which spinal cord
stimulation acts to abate pain stimuli in rats (Shealy et al., 1967). The release of an inhibitory
neurotransmitter Gamma Amino Butyric-Acid (GABA) leads to a decrease in extracellular
glutamate concentration in the dorsal horn. Even though there is clear evidence of successful
outcomes with this technique, the mechanism of action of spinal cord stimulation is still not
completely understood (Wolter, 2014).
Linderoth et al, demonstrated that intrathecal administration of sub-effective doses of
baclofen enhanced spinal cord stimulation analgesia in both human patients and animal models
(Lindroth et al, 2008). Baclofen is an agonist of gamma amino butyric acid, and it is used as a
muscle relaxant and an antispasmodic agent in treating muscle symptoms such as spasm, pain,
and stiffness caused by multiple sclerosis, spinal cord injury or other spinal cord disorders
(Richard D, et al., 1989). Baclofen can be administered to the patient either orally (by mouth) or
intrathecally (directly into the spinal cord). Interestingly, the duration of time that the
extracellular GABA level remained elevated exceeded the duration of spinal cord stimulation
(Meyerson, 1997). The findings by Meyerson may indicate a dysfunctional GABAergic reuptake
mechanism after nerve injury.
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Joosten et al, demonstrated that during the early phase of neuropathic pain, the
intracellular GABA content of the dorsal horn neurons decreases, but increases in the later phase
(Joosten et al, 2011). Thus, the involvement of the GABAergic mechanism in the analgesic effect
of spinal cord stimulation may change during the progress of neuropathic pain.
Thus further studies need to be done to look into other mechanisms involved in the
release of GABA during spinal cord stimulation in neuropathic pain.
Serotonin (5-HT)
Spinal cord stimulation also stimulates other neurotransmitters systems in the spinal
cord. Linderoth et al. demonstrated that spinal cord stimulation induces serotonin release in the
spinal dorsal horn of cats (Linderoth et al., 1992). They further showed that increased
endogenous serotonin content after spinal cord stimulation may involve local GABAergic circuitry
(Song et al, 2009). There are several serotonin (5-HT) receptor subtypes (5-HT 1-7), usually seven,
(7) that exert diverse effects on spinal pain processing. Nerve injury will change the expression
and function of these receptor subtypes (Liu et al, 2010, and Suzuki et al, 2005). Song et al., (2011)
expanded the understanding of the role the different spinal serotonin receptors play in spinal
cord stimulation analgesia during neuropathic pain. The authors showed that activation of 5HT2A, 5-HT3, and 5-HT4 receptors in the dorsal horn may contribute to the spinal cord
stimulation induced decrease in pain transmission. Interestingly, 5-HT3 is known to mediate a
fast excitatory response and plays a role in pain facilitation, but surprisingly, according to Song
et al., (2011) activation of the 5-HT3 receptor results in spinal cord stimulation analgesia.
Nerve injury changes 5-HT3 receptor activity. When this occurs, spinal cord stimulation
analgesia is partially mediated through activation of spinal GABAergic interneurons that express
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5-HT3 receptors (Song et al, 2011). Increased release of serotonin increases the expression and
synthesis of dynorphin, enkephalin and GABA within the spinal cord (Li et al., 2003). This allows
for the delayed and prolong analgesic actions of spinal cord stimulation.
Enkephalin and dynorphin are opioid peptides that play an important role in pain
modulation. They are produced in the central nervous system.
Muscarinic and Adrenergic Mechanism
The other two important mechanisms that play an important role in spinal cord
stimulation analgesia involve cholinergic and adrenergic neurotransmission. According to in vivo
micro-dialysis studies, spinal cord stimulation induces the release of both acetylcholine and
noradrenaline in the spinal cord (Schechtmann et al, 2008). In neuropathic rats that responded
to spinal cord stimulation with analgesia, acetylcholine content was significantly elevated in the
dorsal horn of the responding rats alone. The release of acetylcholine is unaffected in
nonresponsive rats (Schechtmann et al, 2008 and Song et al, 2008). Behavioral studies showed
that administering sub-effective intrathecal doses of a muscarinic agonist could transform non
responding animals to responding animals (Song et al, 2008, Linderoth et al, 2013)
Spinal stimulation-induced pain inhibition was completely blocked by intra-thecally
administered atropine and a muscarinic M4 receptor antagonist, and partially attenuated by M1
and M2 antagonists. Thus inhibition of neuropathic mechanical hypersensitivity by spinal cord
stimulation is associated partially with an increased release of acetylcholine that activates spinal
muscarinic receptors (Schechtmann et al., 2008). Radhakrishnan and Sluka (2003) demonstrated
that transcutaneous electric nerve stimulation (TENS), which is another treatment modality
based on the gate theory, also activates a spinal cholinergic mechanism to achieve pain inhibition.
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Acetylcholine and noradrenaline are also capable of exciting spinal GABAergic interneurons by
binding to muscarinic receptors and α1-adrenoceptors, found on GABAergic interneurons, to
produce analgesia after spinal cord stimulation (Chen and Pan, 2004, Zang et al, 2009). Thus,
noradrenaline and acetylcholine may excite spinal GABAergic interneurons to produce analgesia
after spinal cord stimulation (Song et al., 2008).
Antidromic mechanism of the renal afferent nerve
The idea of an antidromic mechanism for SCS effects was initially proposed by Bayliss
(Bayliss, 1901). Bayliss observed that dorsal root stimulation at high intensity induced peripheral
vasodilation mediated by thin fibers. This finding was confirmed by the observation that a high
intensity stimulation of the dorsal roots provoked an increase in muscle blood flow (Hilton and
Marshall, 1980). Hilton and Marshall, (1980) studies demonstrated the antidromic effect of the
dorsal roots L6-S1 on blood flow through the gastrocnemius muscle in anaesthetized cats. The
authors showed that stimulation of the peripheral ends of the ligated dorsal roots with current
pulses of 0.3-0.5msec duration and at intensities most effective in activating the smaller afferent
fibers, for periods of 15-20 sec, produced a 50-60% increase in muscle vascular conductance
which was slow in onset and long outlasted the stimulus.
Foreman et al., 2003 investigated the fiber types responsible for spinal cord stimulationinduced vasodilation. The purpose of this study was to determine if SCS produces cutaneous
vasodilation via antidromic activation of the unmyelinated C-fiber or the small myelinated fibers.
The authors recorded antidromic compound action potential (CAPs) in the tibial nerve in
response to spinal cord stimulation at L2-L3 spinal level. CAPs of small and large myelinated
afferent fibers were observed in response to spinal cord stimulation at all intensities. The authors
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concluded that SCS-induced vasodilation at ≤60% of the motor-threshold may be mediated via
only the myelinated fibers, whereas vasodilation at ≥90% of motor-threshold may also involve
antidromic activation of some unmyelinated C-fibers (Foreman et al., 2003).
Wu et al., 2006, studies investigated the contribution of vanilloid receptor type 1 (VR-1)
containing fibers to spinal cord stimulation induced vasodilation. This study demonstrated that
several vasodilators are contained in sensory nerve endings and are released during SCS. CGRP
(a potent vasodilator) is co-localized in TRPV1 sensory containing terminals. SCS activates TPRV1 containing sensory fibers in the unmyelinated C-fiber or myelinated Aδ sensory fibers.
Activation of TRPV-1 causes the release of CGRP that binds to CGRP-1 receptors in the vascular
endothelium, which initiates the synthesis and release of nitric oxide (NO) from the vascular
endothelium. NO (a vasodilator) binds to the vascular smooth muscle which induces vasodilation
of the vascular smooth muscle. In conclusion SCS-induced vasodilation is predominately
mediated via VR-1 containing sensor fibers (Wu et al., 2006)
Uses of Spinal cord stimulation
Spinal cord stimulation has been used successfully for the treatment of ischemic pain,
angina pectoris and peripheral vascular diseases. Ischemic pain occurs when there is an
imbalance between the oxygen supply and demand. This can also be defined as the pain that
occurs when the peripheral blood flow to tissues is decreased, thus resulting in inadequate
delivery of oxygen (Simpson et al., 2009). Spinal cord stimulation is beneficial for restoring this
balance between oxygen demand and supply through several different mechanisms (Linderoth
and Foreman, 1999).
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In the case of the ischemic pain of refractory angina pectoris, which is very severe and
unresponsive to anti-ischemic therapies, relief can best be achieved when spinal cord stimulation
is applied at the T1-T2 level, inducing paresthesia covering the precordial chest (Jessurun et al.,
1996). Aside from placement of the electrode at the thoracic level, it should also be noted that
placement at a higher cervical level may provide efficient pain relief as well (Gonzalez et al.,
1998). Several studies have supported the anti-anginal effect of spinal stimulation, which
resulted in a decrease in the frequency of angina attacks. The mechanism of action behind the
anti-anginal effect of stimulation is not clearly understood and is still debated among researchers.
Chandler et al. (2003) focused on the mechanism of cardiac pain suppression by spinal cord
stimulation. The authors could not determine if the main anti-anginal effect was due to direct
inhibition of nociceptive transmission, or mediated by a local redistribution of blood flow and a
decrease in coronary oxygen demand (Linderoth and Foreman, 1999). According to their study,
they believed that local redistribution of blood flow and a decrease in coronary oxygen demand
could be the result of cardiac sympathetic depression resulting in the anti-anginal effect. Other
studies have debunked Chandler’s views and proposed that endogenous opioids are released
into the cardiac circulation during spinal cord stimulation. This could be the reason for local
sympathetic suppression (Eliasson et al., 1998).
Location
Easily accessible large diameter afferent fibers are located at the dorsal column of the
spinal cord. Hence, this makes the dorsal column an ideal location for applying electrical
stimulation (Linderoth and Foreman, 1999). When an electrode (cathode) carrying current is
placed on the dorsal column, it produces an electric field that stimulates spinal sensory fibers.
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This stimulation recruits large diameter low threshold fibers located in the dorsal root first,
before closing the gates to the dorsal horn. For pain control it is recommended to keep the
electrode near the midline (Oakley J.C., 2002).
The specific spinal segment selected for stimulation in humans and animals is an
important determinant of clinical results. The stimulating electrode is usually placed superficially
on the spinal cord ranging from approximately T7-T8 (Meglio M, et al., 1981) to T10 (Jacobs et al.,
1990) or to lower regions of the thoracic spinal cord (Broseta J, et al., 1986).
John et al., compared the effect of dorsal column stimulation at different stimulation
sites; which were T11, T13 and L2. The stimulation parameters used at each of the three sites were
0.2 mA at either 25 or 50 Hz, or 0.6 mA at either 25 or 50 Hz, at a pulse duration of 0.2 ms-1.
Their results demonstrated that the largest changes in blood flow and vascular resistance
to the legs occurred during dorsal column stimulation at the L2 spinal segment, using a stimulus
intensity of 0.6 mA at either 25 or 50 Hz (John E et al., 1996).
To increase cutaneous blood flow to the lower extremities, the spinal segment selected
for stimulation is at the level of L2-L3. Stimulation at T10 and above reduces peripheral blood flow
to the lower extremities. Studies have shown that the vasodilation effect of L2-L3 spinal
stimulation is abolished, when the spine is transected at T13 or muscimol (A psychoactive drug,
which is a potent GABAa agonist, when administered it alters neuronal activities in multiple
regions including the cerebral cortex, hippocampus and cerebellum) is applied topically on the
dorsal surface of the spinal cord (Wu et al., 2008). Linderoth et al. using rat models, placed the
electrode on the spinal cord at the level of T12-L1 level (Linderoth B et al., 1994). Thus, dorsal
column stimulation in either human or animal studies can be applied anywhere from the lower
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thoracic region (T12) to the upper lumber region (L2-L3) of the spinal cord to increase blood flow
to the lower extremities.
Electrical Parameters
All spinal cord stimulation parameters (amplitude, pulse width, frequency) influence the
interaction of stimulation with the nervous system and impact the delivery of charge. The pulse
is the basic unit of electrical stimulation in neuromodulation. It consists of a sustained delivery
of a specific amount of current amplitude, which is measured in volts (V), for a specific amount
of time measured in microseconds (µs). Each pulse is followed by an equal flow of current in the
opposite direction to balance the charge. This is also a safeguard against electrode-tissue damage
due to chemical reactions that might result from charge buildup (J.P Miller, et al., 2016).
Amplitude and pulse width
In amplitude controls, two types of systems are involved: a voltage-controlled system and
a current-controlled system. With regards to the voltage-controlled system, amplitude is
prescribed as the potential difference (V) applied to the electrode surface. In this case, the actual
flow of current is dependent upon impedance at the electrode-tissue interface. The currentcontrolled system delivers a prescribed current, thus allowing the voltage to vary with
impedance. As long as the impedance is stable over time, there would not be a clinical difference
between the constant voltage and constant current systems (Schade et al., 2010). Another factor
that has a great impact on the stimulation amplitude required is the spinal cord movement effect
and cerebral spinal fluid thickness. Pulse width refers to the length of time each pulse of current
is applied. A narrow pulse width will require a high amplitude to activate a neuron or axon when
strength duration is considered, while a wider pulse width will require a lower amplitude
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(Jonathan P et al., 2016). Therefore, the threshold for the generation of an action potential will
typically follow a hyperbolic curve.
Frequency
The frequency parameter in spinal cord stimulation is defined as the number of pulses
per second or hertz. This parameter can be adjusted to be effective. The frequency most
commonly used in clinical practice ranges from 40-100 Hz (North et al., 1993). Several studies on
spinal cord stimulation have demonstrated that the frequency can be an important determinant
of activating specific pain relieving mechanisms. For example, in transcutaneous electrical
stimulation and electro-acupuncture, low rate frequency (2-10Hz) activates µ-opioid receptor
pathways, whereas high rate therapy (100 Hz) activates endogenous ȡ-opioid systems (Ulett et
al., 1998). When frequencies around 50 Hz are used, the dorsal horn GABAergic neurons are
activated. Spinal cord stimulation (SCS) also activates interneurons that use other transmitters
such as acetylcholine and adenosine (Linderoth et al., 2008), serotonergic cells in the
rostroventromedial medulla (Song et al., 2011), and nuclei in the locus coeruleus region
containing norepinephrine (Song et al., 2013). Frequencies at higher rates induce greater blood
flow than frequencies at lower rates.
In humans during spinal cord stimulation, the perception threshold is the voltage at which
the patient starts to experience paresthesia. The discomfort threshold is the voltage at which the
patient cannot withstand the paresthesia anymore. The usage range is the difference between
the perception threshold and the discomfort threshold (Oakley J.C., 2002).
In animal models, the motor threshold is used to calculate the stimulation intensity or
voltage. The motor threshold is determined by gradually increasing the stimulation voltage from
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zero to the point where muscle contraction is visible. The contraction observed is as a result of
stimulating the dorsal column afferent sensory fibers. Stimulation of the afferent sensory fibers
produces a reflex response that activates the motor neurons, which results in muscle contraction
(Wu et al., 2008). The parameters used in conventional spinal cord stimulation include a
frequency of 50 Hz, at a pulse duration of 0.2ms. The stimulation voltage is determined
individually, usually at 40-60% of the motor threshold. (Song et al., 2014).
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CHAPTER II
CURRENT STUDY
Purpose of the study
The purpose of this study is to understand the mechanism behind which dorsal spinal
stimulation increases renal sodium and water excretion. This research answered the following.
Does the renal afferent nerve affect renal changes resulting from spinal cord stimulation,
by retrograde transmission of the electrical impulse?
Do renal changes resulting from spinal cord stimulation, occur as a result of a modification
of the renal efferent nerve output?
This work will help determine effective therapies for the treatment of resistant
hypertension. Spinal cord stimulation has been used for more than 30 years, and is effective in
managing severe conditions like chronic pain, and ischemic pain, due to its ability to increase
peripheral blood flow. Previous studies in the Knoblich laboratory have investigated the effect of
dorsal column spinal stimulation on urinary sodium excretion, and showed that unilateral spinal
cord stimulation at T11-T12, with a stimulation voltage of 67% of the motor threshold, a frequency
of 50 Hz, and a duration of 0.2 ms-1, is effective in increasing urinary sodium and water excretion
in the spontaneously hypertensive rat (SHR). (Mager and Knoblich 2003).
Additional studies in this lab have also shown that the dorsal spinal cord stimulation
induction of urinary sodium and water excretion is not the result of an increase in renal blood
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flow or a change in mean arterial pressure. Furthermore, the renal response was eliminated by
renal denervation, which destroys both the afferent and efferent components of the renal nerve.
The current study will determine the role of the sensory (afferent) portion of the renal
nerve in the renal response to spinal stimulation. For this project, we will use a spontaneously
hypertensive rat that will undergo dorsal rhizotomy of the renal nerves, which is selective
destruction of only the afferent portion of the renal nerve.

Hypothesis
The renal afferent nerve is responsible for transmitting sensory stimuli from the kidney
to the spinal cord. Electrical stimulation of the dura of the spinal cord at the level in which these
nerves enter the spine, could elicit a reciprocal or retrograde transmission on the afferent renal
nerve that would travel back to the kidneys, thus affecting renal changes. We hypothesize that
electrical stimulation of the dorsal column of the spinal cord affects renal changes by retrograde
transmission of renal stimuli from the spinal cord back to the kidney. This hypothesis will be
tested by selectively ablating (severance of) the renal afferent nerve alone, while keeping the
renal efferent nerve intact.
Hypothesis 1: The renal afferent nerve is responsible for transmitting a retrograde signal
to the kidney, during dorsal spinal simulation that affects renal sodium excretion
Hypothesis 2: Severance of the dorsal (afferent) root of the renal nerve, just distal to the
dorsal root ganglion, will eliminate the effect of dorsal spinal stimulation on renal sodium
excretion.
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Animal model
Spontaneously hypertensive rats (SHR strain) are an excellent model of primary
hypertension and have been used to study cardiovascular disease (Pinto et al., 1998). Okomoto
and colleagues obtained this rat strain in the 1960s by selective inbreeding Wistar-Kyoto rats with
high blood pressure (Okamoto and Aoki, 1963). Hypertension begins at 5-6 weeks of age, with
systolic pressure between 180 and 200mmHg in the adult (Conrad et al., 1995).
Hypertensive development in spontaneously hypertensive rats is somewhat related to
the kidney. Kidneys transplanted from the SHR strain to a normotensive Wistar rat increased
blood pressure in the recipient. Conversely transferring a kidney from a Wistar strain to SHR
normalized blood pressure in the recipient (Kawabe et al., 1978). This is only effective if
transplantation occurs at a young age, before hypertension develops in the donor. Thus, this
supports a role for the kidney in the development of hypertension in the SHR.
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CHAPTER III
MATERIALS AND METHODS
Animal Care
A total of thirty two (32) male spontaneously hypertensive rats (SHR), ranging
from 14 to 20 weeks of age, were raised in the animal colony at Minnesota State University,
Mankato. The rats were allowed to reach a minimum age of 14 weeks to ensure that
hypertension was well established. The rats were housed in standard rat cages, given standard
rat chow (Lab Diet 5001 Rodent Diet; PMI Nutrition International LLC, Brentwood, MO) and water
ad libitum. The rats were at a controlled temperature of 21 ± 2°C, and were kept on a 12-hour
day/night light cycle. The rats were randomly assigned to one of the following study groups.
Control Not-Simulated (CNS) - Intact nerves/no stimulation (8 rats)
Control Stimulated (CS) - Intact nerves/ bilateral dorsal spinal stimulation (8 rats)
Denervated Not-Stimulated (DNS) - Dorsal rhizotomy/no stimulation (8 rats)
Denervated Stimulated (DS) - Dorsal rhizotomy/ bilateral dorsal spinal stimulation (8 rats)
All rats were subjected to all surgical procedures except in the intact rats, the dorsal root
was not transected, and in the unstimulated rats, no stimulation was applied.
Exclusion criteria include; incidental death of rats, inability to collect urine, or a sudden
drop in mean arterial pressure below 100 mmHg.
Surgical Preparation
The date of the surgery, the rat's date of birth, weight, anesthetic dose, volume of
saline delivered, and duration of surgery were recorded. The weight of the rat was measured in
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grams, using a weighing balance (A&D Weighing EK-3000EP intrinsically safe portable balance
3000g × 0.1g). The rat was initially anesthetized with isoflurane in O2, (3%, 1.0 L/minute) using a
vaporizer (Model 100 Vaporizer; Surgi Vet,Waukesha, WI) and an anesthetic chamber.
Anesthetic gas was delivered until the rat was no longer responsive. Isoflurane was used
initially to ease the stress of the injection of the primary anesthetic, which was Inactin
(thiobutabarbital sodium) 100 mg/kg i.p. Inactin was chosen for its long lasting anesthetic effect,
and minimal effect on the cardiovascular system. Response tests were conducted, such as the
blink reflex and response to tail pinching to determine proper anesthetic depth. Once the rat
reached sufficient anesthetic depth, the incision sites (neck, pelvic region, and back) were shaved
with a clipper (Oster model Golden A5, McMinnville, TN). After shaving, the rat was placed in
dorsal recumbency on a heating pad (Heating Pad Ultraheat; Sunbeam, Boca Raton, FL), which
was adjusted to maintain rectal temperature between 36-37 °C. Temperature was monitored by
inserting a rectal thermometer (Traceable Digital Thermometer; VWR Scientific) coated with
lubricant (Surgilube; Fougera, Melville, NY) into the rectum, and taped to the tail.
A ventral midline incision with a sterile surgical blade (#10 Henry Schein; Southall,
England) was made in the neck region of the rat. The trachea was exposed via blunt dissection,
and a cut was made with a small surgical scissors (105 mm micro dissecting scissors HSB 010-10;
Hammacher Instrument, Solingen, Germany) just below the larynx for the insertion of an
endotracheal tube (PE 240; Becton Dickinson) to aid respiration.
Placement of the Jugular Vein Catheter for Saline Infusion
The jugular vein was cannulated to allow the infusion of saline (0.9% sodium
chloride, USP; Baxter Healthcare Corp.) to maintain adequate hydration during the experiment.
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Using an infusion pump (PHD 2000 Programmable; Harvard Apparatus, Holliston, MA), saline was
infused at a rate of 15 ml/kg/hr. The jugular vein was isolated on the left side through the same
midline incision used to isolate the trachea. Once isolated the jugular vein was ligated with suture
at the distal end, to prevent bleeding upon cutting. With the aid of magnifying lenses (Optivisor;
Doneqan Optical Co.), a small cut was made in the lumen of the jugular vein with a micro
dissecting scissors (3", straight, tip 0.3mm RS-5610; Roboz Surgical Instrument). Care was taken
to avoid complete transection of the vein. A section of saline filled tubing (PE 50; Becton
Dickinson) connected to a three-way stopcock (Baxter Healthcare Corp., 2C6240) via a tubing
adaptor (Becton Dickinson, 23G) was inserted into the vein, and secured using nylon suture. To
ensure proper insertion into the lumen of the jugular vein, a saline filled syringe was attached to
the stopcock, the system was opened and a negative pressure was applied until blood was
observed flowing into the catheter. The blood was re-infused by placing positive pressure on the
syringe and then the system was closed. The stopcock was attached to tubing which was attached
to a 30 ml luer lok syringe (Becton Dickinson) that was loaded onto the infusion pump. A flow
rate of 15ml/kg/hr was entered onto the pump controls and infused for the duration of the
procedure, to keep the rat hydrated and able to produce urine.
Placement of the Carotid Artery Catheter for Measurement of Blood Pressure
The same midline incision that was used to isolate both the trachea and jugular
vein, was used to isolate approximately a one centimeter section of the left carotid artery. The
distal end of the carotid artery was ligated with nylon suture. On the proximal end of the carotid
artery, a micro aneurism clip was placed to prevent blood loss. With the use of magnifying lenses,
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an incision was made into the carotid artery with microscissors, which was followed by the
insertion into the vessel of a heparinized saline (0.3 ml heparin per 50 ml saline) filled tube (PE
50, Becton Dickinson), connected to a three-way stopcock with a tubing adaptor. Once the
catheter was inserted, it was secured with suture, and tested for correct positioning. This was
done by removing the aneurism clip, turning the stopcock to open the system, and observing for
blood flow into the tubing. The blood was returned to the vascular system by the infusion of
heparinized saline. The stopcock was attached to a pressure transducer connected to Biopac
hardware (Biopac Systems Inc.), and a computer. Arterial blood pressure and heart rate were
recorded, and stored on the computer for later analysis.
Placement of the Bladder Catheter for the Collection of Urine
The bladder was exposed via a small scalpel incision on the ventral midline, just
anterior to the pelvic bone. The cranial edge of the bladder was exteriorized. Then, a small pursestring suture was placed in the cranio-ventral wall of the bladder, using a curved needle (Regular
Surgeon’s Round Bodied ½ circle taper point needle; Miltex Instruments, Bethpage, NY) and nylon
suture. A small cut was made in the center of the purse string, using a small scissors (105 mm
microscopic scissors HSB 010-10; Hammacher Instrumente, Solingen, Germany). A tube (PE 240,
Becton Dickinson), flamed at one end to create a lip, was inserted. The purse-string was tightened
around the tube, just beneath the lip to secure it into the bladder. Any active bleeding on the
bladder was alleviated by surgical cautery (Martin Electrosurgical Unit MD 62; KLS Martin,
Tuttlingen, Germany). The tube was allowed to exit the abdomen ventrally, and the abdomen
and skin was closed around the tube with a simple interrupted suture pattern, using nylon suture
and a needle (Regular Surgeon’s surgical needle 3/8 circle reverse cutting edge; Miltex

43

Instruments, Bethpage, NY). This ensured the collection of all urine produced over the duration
of the procedure.
Procedure for Laminectomy
All rats underwent laminectomy and exposure of the dorsal roots. The rat was
placed on its ventral surface, taking care to preserve the placement of the catheters, particularly
the bladder catheter. The posterior of the rat was supported by a board with an opening in it,
through which the bladder catheter protruded, which allowed urine to be collected unimpeded.
The dorsal portion of the spine was palpated to locate the tall tenth thoracic vertebrae (T10), and
the skin was marked with a marking pen.
A skin incision was made with a #10 scalpel to expose the spine from T9-L1. The
dorsolateral portions of the spinal cord at T9-T13 junction was exposed by scraping off the
overlying muscle with a scalpel. Once sufficient exposure was obtained, the rat was immobilized
for the laminectomy, using a stereotaxic device (Lab Standard Stereotaxic Single unit 56100 with
spinal cord surgery adaptor). The rat was secured to the device bilaterally, using the articulating
processes of T9 and T13. Once the rat was in place, a surgical microscope (Stereo Zoom 4; Leica
Microsystems) was used to aid in the laminectomy, which was performed by gently clipping the
bone at T11-T12 away with a fine bone ronguer. Bone at T11-T12 was carefully clipped away until
enough spinal cord was exposed to be able to successfully place the electrodes bilaterally on the
dura of the dorsal surface of the spine between T11 and T12.
Procedure for Dorsal Rhizotomy
Additional bone removal was required to expose the dorsal roots of T11 and T12.
The dorsal root ganglion was carefully exposed bilaterally at the intervertebral foramen by gently
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clipping away the bone. Great care was taken to ensure no damage to neurological tissue
occurred. On each side, the dorsal roots of T11 and T12 were followed proximally from the
ganglia to the point at which they entered the spine. Using a surgical microscope, each dorsal
root was identified and cut proximal to the dorsal root ganglia using a 20-gauge beveled needle
(Kendall; 20 G 1 ¼) with the tip bent at a 90°angle. Dorsal root was transected in the denervated
groups only. Extreme care was taken to preserve the ventral roots.
Collection Periods
A 45-minute equilibration period followed the surgical setup. Following the
equilibration was six, fifteen-minute collection periods: one pre-stimulation period (Baseline),
one period during-stimulation (period 1), and the remaining four periods (periods 2 – 4) poststimulation. During these periods, urine was collected along with recordings of blood pressure
(mmHg), and heart rate (beats/min). Urine was aspirated from the tubing and bladder using a 1
ml syringe (Becton Dickinson) with tubing (PE 50, Becton Dickinson) attached, and urine was
placed into a graduated 1-ml syringe (Becton Dickinson) with the tip cut off. Urine volume was
recorded to the nearest tenth of a milliliter, the syringe tip was covered with para-film (Pechiney
Plastic Packaging Company; Chicago, Ill.), and urine was stored in the refrigerator (at 10°C) for
later sodium analysis by flame photometer.
Motor Threshold Determination and Spinal Stimulation
In the two groups of rats receiving stimulation (CS and DS), the motor threshold
was determined just prior to the second collection period (stimulation period). This was
ascertained by placing two copper wires (Cathode-positive) with the tip wrapped around like a
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ring, one on each side of the dorsal spinal column at T11-12. A needle (Anode-negative) was
placed one on each side, in the paravertebral muscles.
The cathode (red) and anode (black) was connected to the positive (+) and negative (-)
poles of the stimulator (Grass), respectively. Following precise placement, a small amount of
conductive electrolyte gel (Signa Gel, Parker Laboratories Inc., Fairfield, NJ), was coated over the
cathode to ensure proper conduction at low voltage. The stimulator was set at 2 pulse per
seconds (hertz), and 0.2 seconds duration. The voltage was gradually increased until the
paravertebral muscles began to twitch. This voltge was recorded as the motor threshold. The
intact nerve and dorsal rhizotomy, no-stimulation groups (CNS and DNS) all underwent an
identical procedure as the stimulated groups, with the same time delay in calculating the motor
threshold between baseline and period 1 in the stimulated groups, but did not receive any
electrical stimulation. Dorsal spinal stimulation occurred during period 1 with the parameters of
50 pulses per second, 0.2 seconds duration, and 0.66% of the motor threshold voltage.
Urine Collection and Sodium Determination by Flame Photometry
The urine samples collected during six 15-minute collection periods were analyzed
for sodium content using a flame photometer. Any sample less than 0.30 ml was diluted to 0.3
volume with distilled water, to ensure an adequate volume for the analysis. The total sodium
excreted was calculated by multiplying the sodium concentration by the final volume in the
sample. Sodium concentration was determined by following the calibration and operation
procedures of the flame photometer outlined in the instrument guide and instruction manual.
The final sodium concentration (mmol/l) was divided by 1000 to get the sodium concentration
per ml, and this value was then multiplied by the final diluted volume, producing the total sodium
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excreted in the 15-minute period. This value was divided by the rat’s weight (kg) and multiplied
by 1000 to get a final value in µmol/kg/15min.
Measurement of Blood Pressure and Heart Rate:
Computer recordings of mean arterial blood pressure and heart rate were analyzed using
the Biopac software. Mean values were measured for each 15-minute period and transferred to
a Microsoft Excel worksheet.

Data Analysis
Heart rates (bpm), urine volume (µL/kg), blood pressure MAP (mmHg) and urinary sodium
excretion rates (UNa, µmol/kg/15min) were averaged for each group/period and reported as
mean ± standard error. The change-in data for each rat was calculated by subtracting the
measured data of each of the periods 1 through 5, from the baseline value, and this was
expressed as ∆MAP, ∆Uv, and ∆UNa.
Sigma plot 12.5 program was used for statistical analysis. UNa, MAP, HR, and Uv were
compared within and between groups using a two-way ANOVA with repeated measures. Also,
the change in data of period 1 through 5 from baseline which was expressed as ∆MAP, ∆UV,
∆UNa, were compared within and between groups using two-way ANOVA with repeated
measures. The above data were compared between each treatment groups (II AND IV) and their
control groups (I and III) using one-way ANOVA. Mean baseline and mean sum of excretion data
for period 1-5 were compared among groups using a one way ANOVA. Statistical significance was
accepted when p<0.05. Group II and IV were compared with group I and III respectively, to
determine the effect of dorsal spinal stimulation on sodium excretion in intact and denervated
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rats. Groups III and IV were compared to groups I and II respectively to determine the baseline
effects of denervation.

48

CHAPTER III
RESULTS
General information:
In this study thirty two (32) male spontaneously hypertensive rats (SHR) were randomly
assigned into four (4) groups. The Control Not-Stimulated (CNS) rats, considered a control group,
in which the renal afferent nerve was intact and rats received no dorsal column stimulation, was
compared with the Control-Stimulated (CS) rats, which underwent dorsal column stimulation. In
the Denervated-Not-Stimulated (DNS) rats, renal afferent denervation was done without
bilateral dorsal column stimulation, and this was used as a control for the Denervated-Stimulated
(DS) group, which went through both renal afferent denervation and bilateral dorsal column
stimulation. In order to determine the effects of renal afferent denervation on urinary sodium
excretion, the DNS and DS groups were compared to the CNS and CS groups, respectively.
Mean age, body weight, saline infusion rate, stimulation intensities and surgery times are
shown in Table 1 for all groups. One way anova was used to compare 5 parameter among the
four (4) groups. Statistical significance was accepted when P<0.05. No difference among the
groups was found in any of these parameters.

Urinary Excretion
Bilateral Dorsal Spinal Cord Stimulation in SHR with Intact Renal Nerves
The mean arterial pressure, heart rate and urine sodium excretion was measured in six
15-minute increments. The pre-stimulation period is considered as baseline period for
comparison of the data.
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The stimulation period is considered as the period following baseline in which stimulation
was done for the entire 15 minutes (Period 1). Stimulation was removed, and 4 additional
collection periods followed (periods 2-4).
Urinary sodium excretion is shown in Figure 1A. Although stimulation during period I
caused an increase in urinary sodium excretion, when compared with baseline (57.93 vs 31.53
µmol/kg/15min), this was not statistically significant P=0.071. In the CNS group, which received
no stimulation, urinary sodium excretion during periods 1 through 5 did not change significantly
from baseline.
Comparison between like periods in the CS and CNS groups showed that there was no
significant difference (Figure 1A). However, when the data was normalized as the change from
baseline (Figure 1B), a statistically significant difference was found (P=0.02), (F=3.177) concerning
treatment x time, when CS was compared with CNS. However there was no statistically significant
difference in any individual period when like periods were compared between groups.
Mean baseline and mean sum of sodium excretion for period 1-5 in each of the 4 groups
showed that there was no significant difference (P=0.105 and P=0.561 respectively) (Fig 1C).
Mean sum of increase in sodium excretion over baseline for period 1-5 in each of the 4 groups
showed that there was no statistical difference (P=0.703) (Fig 1D).
Urine volume for each period is shown in Figure 2A. A significant difference was found in
treatment x period when CS was compared to CNS (P= 0.016). Comparison of like periods
between CS and CNS showed a significantly higher urine volume in the CS group than the CNS
group during baseline (P=0.013), Period 1 (P=0.003) and period 2 (P=0.027). In the CNS group,

50

urine volume was increased significantly over baseline during period 5. When data was
normalized as the change from baseline, the difference in treatment x time remained between
the CS and CNS groups.
Mean baseline and mean sum of urine volume for period 1-5 in each of the 4 groups is
shown in (Fig 2C). A statistical significant difference was found within mean baseline when CS
group was compared with CNS group (P=0.009). Mean sum of urine volume for period 1-5 in each
of the 4 groups showed no statistical significant difference (P=0.561)
Mean sum for change in urine volume for period 1-5 showed no statistical significant
difference (P=0.224) (Fig 2D).

Bilateral Renal Denervation
DNS and DS went through bilateral renal afferent denervation before collecting the data
(urine sodium excretion, mean arterial pressure and heart rate). In these groups baseline is the
first data collection period post denervation, (directly following the equilibration period). No
statistically significant differences were found in sodium excretion between the DS and the DNS
rats during any individual period, or in treatment x time (Figure 1A). The same was observed
when CNS was compared with DNS, in that the results showed no statistical significant difference.
When sodium excretion was normalized as the change from baseline, there was no
significant difference when DNS was compared with DS during any time periods, or when
treatment x time was evaluated. Furthermore, no differences were found when the denervated
groups were compared to the intact groups.

51

Urine volume was not different between the DS and DNS groups during any individual
period, or when treatment x time was compared (Figure 2A). Urine volume did not change from
baseline during any period in either group. When urine volume was normalized as change from
baseline, and treatment x time was compared, no difference was found between the two
denervated groups (Figure 2B). When denervated rats were compared to intact rats, a treatment
x time difference was noted between the DNS and the CNS groups, both with raw urine volumes,
and when data was normalized as change from baseline. There was a significance difference
during period 5 when compared to baseline in DNS group
DNS and DS did not show any significant difference when both groups were compared.
The same was observed when CS and DS was compared, result showed no significant difference.

Mean Arterial Pressure (MAP)
Since urinary sodium excretion is affected by mean arterial pressure, the mean arterial
pressure (MAP) was monitored for each rats. There was no statistical difference in mean arterial
pressure between any of the groups, or any of the periods (Figure 3A). A trend of lower pressure
was observed in the denervated groups, and this was significant only when the DS was compared
to the CS group (P = 0.037). In all groups, mean arterial pressure gradually declined during the
course of the acute experiment, but values were not significantly lower than baseline. When
MAP was normalized as the change from baseline (Figure 6), no differences were found between
the groups.
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Heart Rate
There was a statistical significant difference in heart rate when treatment x time was
compared between the CS and CNS groups (Figure 4A). The CNS group showed a trend of a
gradual decrease in heart rate in period 1, through period 3, which then increased in period 4
and 5 but not to the level of the baseline (difference not statistically significant).
The CS group showed a gradual increase in period I from baseline, which then maintain a
fairly constant heart rate in period 3 through 4 after which it decrease a little bit in period 5
(although the difference is not statistically significant). When heart rate was normalized as the
change from baseline, the CS rats had a significantly greater increase in heart rate when
compared to the CNS rats, during periods 2, 3, and 4. (Figure 4B), and an overall greater increase
in heart rate (treatment effect) than the CNS group.
The denervated groups showed no significant differences between or within groups in
heart rate, (Figure 4A), nor any difference when heart rate was expressed as the change from
baseline (Figure 4B). Furthermore, no differences were found between the denervated groups
and the intact groups.
Data Exclusion
Rats were excluded from the data analysis for the following reasons
Sudden death, upon postmortem the lungs shows a grey, flat to raised foci
randomly distributed throughout the lungs (6 rats)
Heat stress resulting in sudden rise in MAP (1)
Death due to excess infusion of heparin-saline (1)
Collected urine samples dried out in 1 ml syringe during storage (1)
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Hyper extension of the limbs and tremors caused by electrode exerting pressure
on the spinal cord (1)
Data discarded due to rats showing signs of dyspnea and hyperpnoea (2)
Data discarded due to pressure going low below 100mmHg (1)
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TABLE
Table 1: Baseline data (age, body weight, saline infusion, stimulation intensity, and surgery time)
in four groups of male SHR rats
Group

Age (WK)

Body Weight (KG)

Saline Infusion Rate
(ml/kg/hr)

Stimulation
Intensity (V)

Surgery Time
(min)

I

20 ± 0.9

0.3 ± 0.0

5.1 ± 0.1

0±0

226.1 ± 6.6

II

20.1 ± 1.2

0.3 ± 0.0

5.0 ± 0.1

0.8 ± 0.1

221.7 ± 4.0

III

19.8 ± 0.6

0.3 ± 0.0

5.0 ± 0.2

0±0

227.0 ± 6.7

IV

18.6 ± 0.5

0.3 ± 0.0

5.2 ± 0.1

0.7 ± 0.0

242.4 ± 7.1

Values are reported as mean ± standard error
Control Not-Stimulated (CNS): Intact Renal Nerve, Non-stimulated
Control Stimulated (CS): Intact Renal Nerve, Stimulated
Denervated Not-Stimulated (DNS): Dorsal Rhizotomy, Non-stimulated
Denervated Stimulated (DS): Dorsal Rhizotomy, Stimulated
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Figure 1A: Mean sodium Excretion during baseline, spinal stimulation (period 1), and post
stimulation collection periods (periods 2-5) in rats subjected to no stimulation (CNS), stimulation
during period 1 (CS), afferent renal denervation and no stimulation (DNS), and afferent renal
denervation and stimulation during period 1 (DS).
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Figure 1B: Mean Change in Sodium from baseline, spinal stimulation (period 1), and post
stimulation collection periods (periods 2-5) in rats subjected to no stimulation (CNS), stimulation
during period 1 (CS), afferent renal denervation and no stimulation (DNS), and afferent renal
denervation and stimulation during period 1 (DS).
* P < 0.05 when CS values over time (Treatment × time) are compared with CNS group with P=0.02
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Figure 1C: Mean baseline and mean sum of sodium excretion for periods 1-5 in each of the 4
groups (CNS, CS, DNS, DS).
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Figure 1D: Mean sum of the increase in sodium excretion over baseline for periods 1-5 (change
in Na excretion) in each of the 4 groups (CNS, CS, DNS, DS)
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Figure 1E: Mean Na Excretion during baseline, spinal stimulation (period 1), and post stimulation
collection periods (periods 2-5) in rats subjected to no stimulation (CNS), stimulation during
period 1 (CS), afferent renal denervation and no stimulation (DNS), and afferent renal
denervation and stimulation during period 1 (DS).

60

Change in sodium excretion
80

CNS

70

CS *
DNS

60

DS

50
40
30
20
10
0
P1

P2

P3

P4

P5

-10

Figure 1F: Mean change in Na excretion from baseline, spinal stimulation (period 1), and post
stimulation collection periods (periods 2-5) in rats subjected to no stimulation (CNS), stimulation
during period 1 (CS), afferent renal denervation and no stimulation (DNS), and afferent renal
denervation and stimulation during period 1 (DS).
* P < 0.05 when CS values over time (Treatment × time) are compared with CNS group with P=0.02
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Figure 2A: Mean Urine Volume during baseline, spinal stimulation (period 1), and post
stimulation collection periods (periods 2-5) in rats subjected to no stimulation (CNS), stimulation
during period 1 (CS), afferent renal denervation and no stimulation (DNS), and afferent renal
denervation and stimulation during period 1 (DS).
From SPSS, CNS is greater than baseline during periods 3, 4, and 5, DS during period 5
* P < 0.05 when CS values over time (Treatment × time) are compared to the CNS group
† P < 0.05 when value is compared to the same period in the CNS group
‡ P < 0.05 when value is compared to the baseline in the DNS group
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Figure 2B: Mean Change in urine volume during baseline, spinal stimulation (period 1), and post
stimulation collection periods (periods 2-5) in rats subjected to no stimulation (CNS), stimulation
during period 1 (CS), afferent renal denervation and no stimulation (DNS), and afferent renal
denervation and stimulation during period 1 (DS).
* P < 0.05 when values over time (Treatment × time) are compared to CNS group

† P < O.O5 when CS values are compared to the same period in the CNS group
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Figure 2C: Mean baseline and mean sum of urine volumes for periods 1-5 in each of the 4 groups
(CNS, CS, DNS, DS).
* P<0.05 when values) are compared to CNS group within baseline
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Figure 2D: Mean sum for change in urine volume from baseline for periods 1-5 in each of the 4
groups (CNS, CS, DNS, DS).
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Figure 2E: Mean Urine Volume during baseline, spinal stimulation (period 1), and post stimulation
collection periods (periods 2-5) in rats subjected to no stimulation (CNS), stimulation during
period 1 (CS), afferent renal denervation and no stimulation (DNS), and afferent renal
denervation and stimulation during period 1 (DS).
From SPSS, CNS is greater than baseline during periods 3, 4, and 5, DS during period 5
* P < 0.05 when values over time (Treatment × time) are compared to the CNS group

† P < 0.05 when value is compared to the same period in the CNS group
‡ P < 0.05 when value is compared to the baseline in the DNS group
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Figure 2F: Mean Change in urine volume during baseline, spinal stimulation (period 1), and post
stimulation collection periods (periods 2-5) in rats subjected to no stimulation (CNS), stimulation
during period 1 (CS), afferent renal denervation and no stimulation (DNS), and afferent renal
denervation and stimulation during period 1 (DS).
* P < 0.05 when values over time (Treatment × time) are compared to CNS group

† P < O.O5 when CS values are compared to the same period in the CNS group
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Figure 3A: Mean arterial pressure during baseline, spinal stimulation (period 1), and post
stimulation collection periods (periods 2-5) in rats subjected to no stimulation (CNS), stimulation
during period 1 (CS), afferent renal denervation and no stimulation (DNS), and afferent renal
denervation and stimulation during period 1 (DS).
* P < 0.05 when DS (Treatment only) is compared to CS group
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Figure 3B: Mean change in mean arterial pressure during baseline, spinal stimulation (period 1),

and post stimulation collection periods (periods 2-5) in rats subjected to no stimulation (CNS),
stimulation during period 1 (CS), afferent renal denervation and no stimulation (DNS), and
afferent renal denervation and stimulation during period 1 (DS).
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Figure 4A: Mean Heart rate during baseline, spinal stimulation (period 1), and post stimulation
collection periods (periods 2-5) in rats subjected to no stimulation (CNS), stimulation during
period 1 (CS), afferent renal denervation and no stimulation (DNS), and afferent renal
denervation and stimulation during period 1 (DS).
* P < 0.05 when CS values over time (Treatment × time) are compared with CNS group.
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Figure 4B: Mean Change in heart rate during baseline, spinal stimulation (period 1), and post
stimulation collection periods (periods 2-5) in rats subjected to no stimulation (CNS), stimulation
during period 1 (CS), afferent renal denervation and no stimulation (DNS), and afferent renal
denervation and stimulation during period 1 (DS).
* P < 0.05 when CS value (Treatment only) is compared to CNS group P= 0.035.

† P < 0.05 when CS values compared to the same period in the CNS group.
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DISCUSSION

In previous studies in this lab, spinal cord stimulation (SCS) has been found to effectively
increase urinary sodium excretion (UNa). Mager and Knoblich examined the effect of unilateral
(left) dorsal column stimulation on urine sodium excretion in male SHR rats. These studies,
demonstrated that stimulation at two-third of the motor threshold (67%) at the level of T11-T12,
significantly increased the urinary sodium excretion during periods 4 and 5 (with stimulation
occurring during period 2), when compared with the control group. Spinal cord stimulation at
90% of motor threshold did not increase urinary sodium excretion significantly in these studies
(Mager and Knoblich, 2003).
In another study, Stearns and Knoblich applied unilateral dorsal column stimulation at T12T13 of male SHR and measured urine sodium excretion, mean arterial pressure, heart rate, and
renal blood flow. The authors demonstrated that spinal cord stimulation did not change renal
blood flow, mean arterial pressure or heart rate, but increased urine sodium excretion
significantly in the treatment group during periods 3 and 4 (stimulation occurred during period
2), compared with the control group. Their study concluded that the natriuretic effect of spinal
cord stimulation is independent of alterations in renal blood flow (Stearns and Knoblich, 2007).
Further studies conducted in the Knoblich laboratory in 2016 examined the effect of
bilateral renal denervation on urinary sodium excretion following spinal cord stimulation
(Knoblich and Mellati). These results showed that when stimulation was applied during period 2,
urine sodium excretion increased over baseline values during period 2, 3, 4, and 5. When sodium
excretion was expressed as the change from baseline, the increase from baseline sodium

72

excretion was greater in the stimulated rats than the control rats during periods 2, 3, and 4
(stimulation was applied during period 2). Complete renal denervation resulted in a greater
baseline urinary sodium excretion and a lower mean arterial pressure. Complete renal
denervation reversed the effect of SCS, resulting in a decline in urinary sodium excretion when
compared to baseline. A similar pattern was observed in urine volume, increasing after SCS in
the group with intact renal nerves, but decreasing in the denervated group. Although mean
arterial pressure was not significantly affected by SCS in the intact rats, SCS in the denervated
rats resulted in a sharp decline in MAP, providing a potential explanation for the decline in urinary
sodium excretion.
Based on these prior studies, this research was designed to determine if spinal cord
stimulation increases urinary sodium excretion in SHR by a mechanism involving the renal
sensory nerves. For this purpose, four groups of rats were used. In the CNS group, no intervention
was done, and this group was considered the control for CS group, which went through bilateral
spinal cord stimulation. In the same way the DNS group (dorsal rhizotomy with no spinal cord
stimulation) was designed as the control for the DS group (dorsal rhizotomy with spinal cord
stimulation). Other group comparisons were done to determine the effect of denervation alone.
No significant difference between the groups were found in age, weight, surgery duration
or saline infusion. Therefore, differences between groups cannot be attributed to differences in
these variables.
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Dorsal Column Spinal Stimulation in SHR with Intact Renal Nerves
In this study we observed variability in baseline urine sodium excretion among the rats in
both groups. Similar variations in urine sodium excretion have been observed in other studies
(Stearns and Knoblich, 2007, Marger and Knoblich, 2003, Mellati and Knoblich, 2016). This
variation could be due to hypertension, or small variations in rat health and hydration, or in time
and blood loss during the surgical setup. To account for the effect of high variability in sodium
excretion during the baseline period, the change in urinary sodium excretion from baseline was
calculated.
When data was normalized as change from baseline, bilateral dorsal column stimulation
of the spinal cord at 67% of the motor threshold showed a significant difference in the pattern of
urine sodium excretion (treatment × time) in the stimulated, intact rats (CS) when compared with
the non-stimulated intact rats (CNS). In CS group, urine sodium excretion was increased during
period 1 and decreased during periods 2, 3, 4, and 5. CNS group showed a gradual increase in
urine sodium excretion as time progressed during the acute study. As reported in other studies
in this lab, no significant difference was found in the raw sodium excretion during like time
periods when the two groups where compared.
In neuropathic pain, spinal cord stimulation blocks the phenomenon of “wind-up of wider
dynamic range neuronal response” and this may explain the effect of pain relief. During chronic
noxious stimuli, spinal excitability increases. Consequently, due to central sensitization, pain gets
much worse through the activity of local excitatory interneurons, resulting in even non-painful
stimuli feeling painful (hyperalgesia). Spinal cord stimulation activates large diameter axons
called Aβ fibers in the dorsal horn, which subsequently activate inhibitory interneurons to block
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the local excitatory interneurons and transmission cells (WDR neurons). This blocks the wind-up
process and prolongs analgesic effects (Guan, 2012). The same mechanism may activate the
inhibitory interneurons to suppress afferent WDR renal sensory fibers and decrease the overall
renal sympathetic nerve activity, interrupting the positive feedback loop between renal sensory
input and efferent sympathetic outflow that has been described in hypertensive people and
animal models. Since the sympathetic nerve effect is to decrease sodium excretion, reducing
sympathetic outflow to the kidney would increase renal sodium excretion.
Urine volume increased during period 1 in the intact stimulated group (CS), then declined,
producing a different pattern of excretion (treatment × time) than the intact non stimulated
group (CNS) over the collection periods. Urine volumes in the CS group were significantly higher
than in the CNS group during periods 1 and 2, but were also higher during baseline. When data
was normalized as change from baseline, the CS group again had a significantly different pattern
(treatment × time) of urine volume over time than the CNS group. It is likely that the increase in
urine volume occurred as a result of the increase in urinary sodium excretion. This supports the
hypothesis that spinal cord stimulation increases sodium excretion.
Stimulation increased heart rate in the CS rats, which then remained elevated, resulting
in a significantly different (treatment × time) effect than the CNS rats. Furthermore, when data
was normalized as change from baseline, the heart rate increases following stimulation were
significantly greater than the non-stimulated rats during periods 2, 3, and 4. Mellati’s study
showed that heart rate declined in CS rats, becoming significantly lower than baseline during
period 2. The CNS group in Mellati’s study showed no significant changes in heart rate from
baseline, and remained stable though out the study.
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MAP gradually declined over the course of the acute study in the intact groups, and no
differences were noted in the stimulated rats. This is similar to Mellati’s results in which MAP
declined through the course of the acute study.

Dorsal Column Stimulation in Renal Denervated SHR
Afferent renal nerve ablation (renal afferent denervation) did not alter baseline sodium
excretion, urine volume, or heart rate.

Denervation eliminated the effect of SCS on urinary

sodium excretion and urine volume. This suggests that spinal cord stimulation is unable to
increase urine sodium excretion in the absence of an afferent renal nerve. Bayliss (1901)
demonstrated that dorsal root stimulation at high intensity induced peripheral vasodilation
mediated by thin fibers. Hilton and Marshall (1980) studies confirmed Bayliss observation by
demonstrating the antidromic effect of dorsal root stimulation on blood flow through the
gastrocnemius muscle. The authors showed that dorsal root stimulation with a current pulse of
0.3-0.5msec duration for a period pf 15-20 seconds, produced a 50-60 %increase in muscle
vascular conductance (Hilton and Marshall, 1980).
Foreman et al., (2003) characterized the fiber types responsible for spinal cord
stimulation-induced vasodilation. The authors demonstrated that spinal cord stimulation at ≤60%
of motor-threshold induced vasodilation via antidromic activation of myelinated fibers only.
Spinal cord stimulation of ≥90% of motor-threshold induced vasodilation via antidromic
activation of unmyelinated C-fibers (Foreman etal., 2003).
Wu et al. (2006), demonstrated that spinal cord stimulation activates TRPV-1 containing
sensory fibers in the unmyelinated C-fibers or myelinated Aδ sensory fibers. Additionally the
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authors showed that activation of TRPV-1 containing sensory fibers by SCS would result in the
release of CGRP from sensory nerve terminals which would initiate the release of nitric oxide.
Nitric oxide from the vascular endothelium binds to the vascular smooth muscle to induce
vasodilation (Wu et al., 2006).
Simon et al. 1989, demonstrated that electric stimulation of the afferent renal nerve
elicited a rise in vasopressin release 1 hour after stimulation which gradually returned to the
control level by the third hour after stimulation. Thus, renal denervation may alter vasopressin
release by interruption of the afferent renal nerves.
Denervation resulted in a lower mean arterial pressure than the intact groups, but this
was only significant when combined with stimulation (DS vs CS). Mean arterial pressure gradually
decreased in all groups. Stimulation had no clear effect on MAP in the denervated group when
compared to the other groups. Mellati’s study demonstrated that spinal cord stimulation in renal
denervated SHR significantly decreased mean arterial pressure from an already reduced baseline,
which persisted for the remainder of the acute study. Since this effect was not observed in our
study, it appears that complete renal denervation is needed to produce a decrease in MAP with
SCS.
The effect observed in this study that dorsal rhizotomy decreases baseline mean arterial
pressure has been observed in other studies. Mellati’s study demonstrated that complete renal
denervation lowered MAP, which persisted during the acute study. Frederick et al. demonstrated
a marked sudden decrease in mean arterial pressure after renal denervation (Frederic et al.
2003). Investigators have found that renal denervated animals have a lower plasma renin activity
than intact animals (Collister and Osborn, 1998). This result indicates that the acute or sudden
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decrease in arterial pressure observed after renal denervation may be the result of a decrease in
renin release, which is not unexpected following elimination of the renal efferent sympathetic
nerves, a stimulator of renin release. Another possibility is that renal vasomotor tone might be
reduced in denervated rats, again secondary to loss of renal efferent sympathetic stimulation.
The present study eliminated only the afferent renal nerves, and left the efferent nerves intact.
Thus the smaller effect on MAP in this study may have been through mechanisms not related to
the sympathetic efferent nerves.

Janssen et al. 1989 subjected rats to renal denervation,

selective dorsal rhizotomy or sham studies. Results showed that mean arterial pressures were
significantly lowered in complete renal denervation compared with selective dorsal rhizotomy or
sham. Previous studies have shown that selective deafferention by dorsal rhizotomy in SHR did
not attenuate the subsequent increase in mean arterial pressure, but complete renal denervation
did (Spripairojhikoon et al. 1989). The present study showed a somewhat smaller decrease in
MAP in the denervated group than the intact group but this was only significant when combined
with stimulation (DS vs CS).
Afferent renal denervation produced a different pattern of urine volume excretion
between the non-stimulated groups (DNS vs CNS), both when raw data was analyzed and when
data was expressed as change from baseline. Other studies have shown that there was no
statistical difference in urine volume excretion when non-stimulated groups where compared
(DNS vs CNS) (Mellati and Knoblich, 2016, Mager and Knoblich, 2003, Stearns and Knoblich,
2007). The mechanism by which this unique finding occurred remains unknown. The difference
appears to be a more gradual increase in urine volume excretion in the DNS rats when compared
to the stepper increase in the CNS rats. The higher baseline level in the denervated rats may be
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responsible for the greater stability in urine volumes and could be an effect related to the
elimination of the afferent renal nerve input, which can stimulate vasopressin as mentioned
previously. Lower vasopressin at baseline may have resulted less water reabsorption in the
kidney collecting ducts, resulting in a higher baseline urine volume.
Afferent renal denervation eliminated the effect of SCS on heart rate. No difference in
heart rate in the denervated groups were observed between the SCS rats and the non-stimulated
rats.
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SUMMARY

In this experiment we have confirmed the effect of dorsal rhizotomy on urinary sodium
excretion following dorsal spinal stimulation in SHR. We can conclude that dorsal column
stimulation at the level of T11 – T12 at the voltage of 67% of motor threshold increased urinary
sodium and water excretion from the kidney. This study demonstrated that denervation of the
renal afferent nerve eliminated the response. In renal afferent denervated rats spinal cord
stimulation was unable to increase renal sodium excretion and urine volume. This confirms spinal
cord stimulation works through the renal afferent nerve via a retrograde transmission of
electrical signal back into the kidneys. Furthermore we found that dorsal column stimulation
significantly decreased MAP in the renal afferent denervated group when compared with the
intact group. This is an exciting finding and could be the subject of further experiments to
investigate the mechanism behind it.
Spinal cord stimulation could be a great alternative for the treatment of resistant
hypertension, and less invasive than denervation. Further studies are needed to investigate the
long-term effect of chronic or intermittent spinal cord stimulation on renal and cardiovascular
physiology.

Evaluation of Hypotheses
As mentioned previously the purpose of this experiment is to understand the mechanism
behind which dorsal spinal stimulation increases renal sodium and water excretion via renal
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afferent nerve. For this purpose a couple of hypothesis were considered and all were accepted
as below;
Hypothesis 1: the renal afferent nerve is responsible for transmitting a retrograde signal
to the kidney, during dorsal spinal stimulation that affect renal sodium excretion,
According to the results of ∆UNa in CS group compared to the CNS group, this hypothesis
was accepted.
Hypothesis 2
Severance of the dorsal root of renal afferent nerve, just distal to the dorsal root ganglion,
will eliminate the effect of dorsal spinal stimulation on renal sodium excretion.
The data analysis of UNa, ∆UNa, Uv and ∆Uv showed that severance of the dorsal root
eliminated the effect of SCS.
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